MMP2 and renal cell carcinoma: Our study revealed that FCRLA plays an oncogenic role in RCC development through a mechanism involving MMP2, indicative that a FCRLA‐pERK1/2‐MMP2 signaling pathway could be a potential target for RCC immunotherapy.